Please Wait
Applying Filters...
menu
    • menu
    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-03

    Virtual Booth

    An Enquiry

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    KZR-616

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Kezar Plans Layoffs After FDA Axes Meeting To Discuss Next Trial
    Kezar Plans Layoffs After FDA Axes Meeting To Discuss Next Trial

    17 Oct 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/kezar-plans-layoffs-after-fda-cancels-meeting-discuss-next-trial

    FIERCE BIOTECH
    17 Oct 2025
    Share Share
    Kezar Updates Zetomipzomib Program, Explores Strategic Options
    Kezar Updates Zetomipzomib Program, Explores Strategic Options

    16 Oct 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-10-16/kezar-life-sciences-announces-regulatory-update-on-zetomipzomib-program-in-autoimmune-hepatitis-and

    PHARMIWEB
    16 Oct 2025
    Share Share
    Kezar Life Sciences: FDA Lifts Partial Hold on PORTOLA Trial
    Kezar Life Sciences: FDA Lifts Partial Hold on PORTOLA Trial

    15 Jul 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250715420439/en/Kezar-Life-Sciences-Announces-FDA-Has-Lifted-Partial-Clinical-Hold-on-PORTOLA-Phase-2a-Trial-Evaluating-Zetomipzomib-for-the-Treatment-of-Patients-with-Autoimmune-Hepatitis

    BUSINESSWIRE
    15 Jul 2025
    Share Share
    Kezar Life Reports Positive Results from PORTOLA Ph 2 Trial
    Kezar Life Reports Positive Results from PORTOLA Ph 2 Trial

    25 Mar 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250325918238/en/Kezar-Life-Sciences-Announces-Positive-Topline-Results-from-the-PORTOLA-Phase-2a-Trial-Evaluating-Zetomipzomib-for-the-Treatment-of-Patients-with-Autoimmune-Hepatitis-AIH-and-Reports-Fourth-Quarter-and-Year-End-2024-Financial-Results

    BUSINESSWIRE
    25 Mar 2025
    Share Share
    Kezar Life Sciences to Present PORTOLA Phase 2a Trial Results
    Kezar Life Sciences to Present PORTOLA Phase 2a Trial Results

    24 Mar 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250324687575/en/Kezar-Life-Sciences-to-Present-Topline-Results-from-the-PORTOLA-Phase-2a-Trial-Evaluating-Zetomipzomib-for-the-Treatment-of-Patients-with-Autoimmune-Hepatitis-on-March-25-2025

    BUSINESSWIRE
    24 Mar 2025
    Share Share
    Kezar To Present Zetomipzomib Data In AIH, Lupus Trial Update
    Kezar To Present Zetomipzomib Data In AIH, Lupus Trial Update

    18 Feb 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250218398885/en

    BUSINESSWIRE
    18 Feb 2025
    Share Share